Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Pulmonary emphysema is characterized by airspace enlargement and the destruction of alveoli. Alveolar type II (ATII) cells are very abundant in mitochondria. OXPHOS complexes are composed of proteins encoded by the mitochondrial and nuclear genomes. Mitochondrial 12S and 16S rRNAs are required to assemble the small and large subunits of the mitoribosome, respectively. We aimed to determine the mechanism of mitoribosome dysfunction in ATII cells in emphysema. ATII cells were isolated from control nonsmokers and smokers, and emphysema patients. Mitochondrial transcription and translation were analyzed. We also determined the miRNA expression. Decreases in ND1 and UQCRC2 expression levels were found in ATII cells in emphysema. Moreover, nuclear NDUFS1 and SDHB levels increased, and mitochondrial transcribed ND1 protein expression decreased. These results suggest an impairment of the nuclear and mitochondrial stoichiometry in this disease. We also detected low levels of the mitoribosome structural protein MRPL48 in ATII cells in emphysema. Decreased 16S rRNA expression and increased 12S rRNA levels were observed. Moreover, we analyzed miR4485-3p levels in this disease. Our results suggest a negative feedback loop between miR-4485-3p and 16S rRNA. The obtained results provide molecular mechanisms of mitoribosome dysfunction in ATII cells in emphysema.

Details

Title
Mitochondrial Ribosome Dysfunction in Human Alveolar Type II Cells in Emphysema
Author
Loukmane Karim 1 ; Chih-Ru Lin 1 ; Kosmider, Beata 2 ; Criner, Gerard 3 ; Marchetti, Nathaniel 3 ; Bolla, Sudhir 3 ; Bowler, Russell 4 ; Bahmed, Karim 5 

 Department of Microbiology, Immunology, and Inflammation, Temple University, Philadelphia, PA 19140, USA; [email protected] (L.K.); [email protected] (C.-R.L.); [email protected] (B.K.); Center for Inflammation and Lung Research, Temple University, Philadelphia, PA 19140, USA 
 Department of Microbiology, Immunology, and Inflammation, Temple University, Philadelphia, PA 19140, USA; [email protected] (L.K.); [email protected] (C.-R.L.); [email protected] (B.K.); Center for Inflammation and Lung Research, Temple University, Philadelphia, PA 19140, USA; Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA 19140, USA; [email protected] (G.C.); [email protected] (N.M.); [email protected] (S.B.) 
 Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA 19140, USA; [email protected] (G.C.); [email protected] (N.M.); [email protected] (S.B.) 
 Department of Medicine, National Jewish Health, Denver, CO 80206, USA; [email protected] 
 Center for Inflammation and Lung Research, Temple University, Philadelphia, PA 19140, USA; Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA 19140, USA; [email protected] (G.C.); [email protected] (N.M.); [email protected] (S.B.) 
First page
1497
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
22279059
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2693933610
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.